The W8Experts Diagnostic Approach to Fatty Liver (MASLD)

Section accent: --clay (MASLD pillar, scoped in-family). This is the signature 4-step W8Experts liver pathway.

The idea behind the pathway

Don't just find fat. Find risk.

Finding fat in the liver is easy and, by itself, not very informative. The clinically decisive question is whether there is fibrosis — scarring — because fibrosis stage, not fat amount, is what most predicts serious outcomes. So this pathway is built to separate finding fat from finding risk, and to do it in the right order, with the cheapest, least invasive tests first.

A second principle runs through it: not every patient needs every test. The pathway is a filter. Its job is to reassure the low-risk majority with minimal testing and route the higher-risk minority to the tests — and clinicians — that actually change management. This structure follows AASLD and EASL–EASD–EASO guidance. → What Is MASLD?

STEP 1 — Identify steatosis (is there fat?)

The first question is simply whether the liver contains excess fat.

How fat is detected:

• Ultrasound — the most common first look. Widely available and inexpensive, it shows a "bright" (echogenic) liver when fat is present.
• CT and MRI — often the way fat is found incidentally during scans done for other reasons.
• MRI-PDFF (proton density fat fraction) — the most precise, quantitative fat measurement; used mainly in specialist care and research to track change over time.
• CAP (Controlled Attenuation Parameter) — a fat estimate reported by the FibroScan device alongside its stiffness reading.

The limits of ultrasound — say this out loud: ordinary ultrasound is insensitive to lower amounts of fat (it may miss mild steatosis), it's operator-dependent, and — critically — it does not measure fibrosis. A "fatty liver" on ultrasound is a steatosis finding, full stop. It tells you nothing about scarring, which is why Step 1 is never the end of the workup. → "My Liver Tests Are Normal…"

STEP 2 — Assess metabolic risk (why is the fat there?)

MASLD is metabolic disease, so the second step characterizes the metabolic driver — both to confirm the diagnosis is metabolic and because these findings shape treatment. This is routine, low-cost information:

• BMI and waist circumference — overall and central adiposity. → BMI, Body Fat & Body Composition
• Blood pressure.
• A1c and fasting glucose — for diabetes or prediabetes.
• Lipid panel, especially triglycerides and HDL.
• Liver enzymes (ALT/AST) — useful context, but not a fibrosis test (see Step 3).
• Renal function and a medication review — some drugs affect the liver or the interpretation of tests, and comorbidities influence management.

This step also screens for other or contributing liver disease (alcohol intake, viral hepatitis where relevant, other causes) so the diagnosis isn't assumed to be metabolic by default. → Who Should Be Evaluated?

STEP 3 — Assess fibrosis risk (FIB-4 first)

Now the decisive question: is there scarring? The first-line answer comes from FIB-4 — a score calculated from four routine values (age, AST, ALT, platelet count) that most people already have.

FIB-4 cutoffs (standard adult interpretation):

The age caveat — essential. FIB-4 puts age in the numerator, so scores drift up with age regardless of true fibrosis. In adults aged ≥65, the lower cutoff is raised to about 2.0 to cut down false positives (so a value of 1.3–2.0 in a 70-year-old is often not treated as indeterminate). FIB-4 also performs less well in people under about 35. A low FIB-4 is genuinely reassuring; a high one is a flag, not a diagnosis. → FIB-4 Explained

STEP 4 — Second-line noninvasive testing (measure stiffness)

When FIB-4 is indeterminate or high (or when other features raise concern), the next step measures liver stiffness — a physical surrogate for fibrosis:

• VCTE / FibroScan (vibration-controlled transient elastography) — a quick, painless bedside probe reporting liver stiffness in kilopascals (kPa); higher stiffness suggests more fibrosis. As a MASLD rule-of-thumb (not a fixed line, and varying by lab and cause of disease): roughly <8 kPa is low/reassuring, ~8–12 kPa is indeterminate, and >12 kPa is high risk (some use >15 kPa to flag compensated advanced chronic liver disease). The same visit reports CAP for fat. Distinguish the two numbers: kPa = fibrosis surrogate; CAP = fat.
• MRE (magnetic resonance elastography) — MRI-based stiffness mapping; more accurate than FibroScan and less affected by body habitus, but costlier and less available. Reserved for uncertain or discordant cases.

Elastography is a surrogate, not a biopsy: it measures stiffness, which usually tracks fibrosis but can be distorted (by obesity or probe fit, recent food, or liver congestion). Only a minority of patients ever need this step, and fewer still need biopsy. → FibroScan & Elastography · Liver Biopsy: When It's Needed

The pathway, as a flow

METABOLIC RISK  (who to evaluate — diabetes, obesity, metabolic syndrome …)
        ↓
STEATOSIS  (Step 1: ultrasound / CT / MRI / MRI-PDFF / CAP — find the fat)
        ↓
FIB-4  (Step 3 stratifier: age, AST, ALT, platelets — age-adjusted ≥65)
        ↓
ELASTOGRAPHY  (Step 4: FibroScan/VCTE kPa or MRE — when FIB-4 indeterminate/high)
        ↓
LOWER  ·  INTERMEDIATE  ·  HIGHER  risk
        ↓
MONITOR      ·      INTERVENE      ·      REFER / FURTHER EVALUATE

(Step 2 — metabolic-risk assessment — runs alongside, characterizing the driver and guiding treatment at every stage.)

Read the three endpoints honestly: - Lower risk → MONITOR. Treat metabolic risk; recheck periodically. - Intermediate → INTERVENE. Address the metabolic disease actively; reassess fibrosis. - Higher risk → REFER / FURTHER EVALUATE. Hepatology involvement, consideration of MASH therapy, and — selectively — biopsy. → MASH Medications

"Not every patient needs every test"

This deserves its own heading because both over- and under-testing are common. A metabolically healthy person with a low FIB-4 does not need a FibroScan, an MRE or a biopsy. Conversely, a person with diabetes and metabolic syndrome should not be reassured by normal enzymes and a bright liver on ultrasound alone. The pathway matches the intensity of testing to the probability of at-risk disease — checked against AASLD and EASL–EASD–EASO recommendations — which is what keeps it both safe and proportionate.

SIGNATURE — "What the evidence says: The diagnostic pathway"

• What we know: A stepwise noninvasive pathway (identify steatosis → assess metabolic risk → FIB-4 → elastography) risk-stratifies most people without biopsy; FIB-4 has an excellent low-risk rule-out; elastography adds accuracy for the indeterminate/high group.
• What we think: This sequence is the right default: cheap first, invasive last, biopsy rarely.
• What we don't know: Optimal re-testing intervals, and the best pathway for "lean" MASLD and some discordant cases.
• What patients should do: Expect a sequence, not a single test — and ask specifically where you fall on fibrosis risk, not just whether you "have a fatty liver." → FIB-4 Explained

Questions patients ask

KEEP READING

• FIB-4 Explained — the first-line fibrosis-risk score and its age caveat.
• FibroScan & Elastography — the second-line stiffness test, and fat vs fibrosis.
• "My Liver Tests Are Normal…" — why the workup doesn't stop at normal enzymes.
• Liver Biopsy: When It's Needed — the reference standard, used selectively.
• Who Should Be Evaluated? — deciding who enters the pathway in the first place.

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: AASLD Practice Guidance on MASLD (2023); EASL–EASD–EASO clinical practice guidance; guideline-based FIB-4 cutoffs (<1.3 / >2.67; age-adjusted ~2.0 at ≥65). Educational; not a diagnosis.